MA27638A1 - Utilisation de derives de carbamazepine dans le traitement de l'agitation chez des patients atteints de demence - Google Patents

Utilisation de derives de carbamazepine dans le traitement de l'agitation chez des patients atteints de demence

Info

Publication number
MA27638A1
MA27638A1 MA28522A MA28522A MA27638A1 MA 27638 A1 MA27638 A1 MA 27638A1 MA 28522 A MA28522 A MA 28522A MA 28522 A MA28522 A MA 28522A MA 27638 A1 MA27638 A1 MA 27638A1
Authority
MA
Morocco
Prior art keywords
agitation
treatment
compound
dementia
patients
Prior art date
Application number
MA28522A
Other languages
English (en)
Inventor
Joshua Shua-Haim
Ferenc Martanyi
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA27638A1 publication Critical patent/MA27638A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'invention concerne l'utilisation d'un composé de formule I dans laquelle: (a) R1 et R2 forment ensemble un groupe oxy, ou (b) R1 représente hydrogène et R2 représente hydroxy ou acétoxy, ou un sel pharmaceutiquement acceptable de celui-ci, dans la fabrication d'une composition pharmaceutique servant à traiter l'agitation, en particulier l'agitation comportementale, surtout chez les patients atteints de démence. L'invention concerne également une méthode de traitement de l'agitation; des compositions pharmaceutiques contenant un composé de formule I; une combinaison contenant: (a) un composé de formule I, et (b) au moins un composé choisi dans le groupe constitué par des extraits végétaux nootropiques, des antagonistes de calcium, des inhibiteurs de la cholinestérase, la dihydroergotoxine, la nicergoline, le piracétame, des dérivés de purine, le pyritinol, la vincamine et la vinpocétine; ainsi qu'un emballage commercial contenant ladite combinaison.
MA28522A 2003-04-01 2005-09-30 Utilisation de derives de carbamazepine dans le traitement de l'agitation chez des patients atteints de demence MA27638A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45933803P 2003-04-01 2003-04-01

Publications (1)

Publication Number Publication Date
MA27638A1 true MA27638A1 (fr) 2005-11-01

Family

ID=33131880

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28522A MA27638A1 (fr) 2003-04-01 2005-09-30 Utilisation de derives de carbamazepine dans le traitement de l'agitation chez des patients atteints de demence

Country Status (25)

Country Link
US (2) US20070066593A1 (fr)
EP (1) EP1613328B8 (fr)
JP (1) JP2006522050A (fr)
KR (1) KR20050121236A (fr)
CN (1) CN1767833A (fr)
AT (1) ATE425756T1 (fr)
AU (1) AU2004226805B2 (fr)
BR (1) BRPI0408956A (fr)
CA (1) CA2521371A1 (fr)
DE (1) DE602004020060D1 (fr)
ES (1) ES2323270T3 (fr)
HK (1) HK1090543A1 (fr)
HR (1) HRP20050872A2 (fr)
IS (1) IS8096A (fr)
MA (1) MA27638A1 (fr)
MX (1) MXPA05010608A (fr)
NO (1) NO20054994L (fr)
NZ (1) NZ542554A (fr)
PL (1) PL1613328T3 (fr)
PT (1) PT1613328E (fr)
RU (1) RU2351338C2 (fr)
TN (1) TNSN05247A1 (fr)
TW (1) TW200501962A (fr)
WO (1) WO2004087166A1 (fr)
ZA (1) ZA200507439B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200501962A (en) * 2003-04-01 2005-01-16 Novartis Ag Use of carbamazepine derivatives for the treatment of agitation in dementia patients
GB0424563D0 (en) * 2004-11-05 2004-12-08 Novartis Ag Organic compounds
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
GB0517740D0 (en) * 2005-08-31 2005-10-12 Novartis Ag Organic compounds
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
WO2010019392A1 (fr) * 2008-08-13 2010-02-18 Merck Sharp & Dohme Corp. Dérivés de purine pour le traitement de la maladie d’alzheimer
CN102180965B (zh) * 2011-03-02 2014-01-01 广州金域医学检验中心有限公司 卡马西平免疫原、抗卡马西平特异性抗体、检测试剂及检测试剂盒
CN102183659B (zh) * 2011-03-02 2014-07-02 广州金域医学检验中心有限公司 一种卡马西平检测方法
RU2504367C1 (ru) * 2012-06-05 2014-01-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Амурская государственная медицинская академия" Минздравсоцразвития Российской Федерации Способ коррекции психического состояния пациентов и антиоксидантного статуса при органическом расстройстве личности

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH500196A (de) * 1969-03-10 1970-12-15 Ciba Geigy Ag Verfahren zur Herstellung von neuen Azepinderivaten
US3637661A (en) * 1970-03-04 1972-01-25 Ciba Geigy Corp 10-hydroxy-10 11-dihydro-dibenzazepine derivative
US5827819A (en) * 1990-11-01 1998-10-27 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
JP3057471B2 (ja) * 1993-06-07 2000-06-26 武田薬品工業株式会社 アンジオテンシンｉｉ介在性諸疾患の予防または治療剤
PT101732B (pt) * 1995-06-30 1997-12-31 Portela & Ca Sa Novas di-hidrodibenzo<b,f>azepinas substituidas processo para a sua preparacao composicoes farmaceuticas que as contem e utilizacao dos novos compostos na preparacao de composicoes farmaceuticas empregues em doencas do sistema nervoso
US5736647A (en) * 1995-08-07 1998-04-07 Oval Corporation Vortex flow meter detector and vortex flow meter
US20020086067A1 (en) * 1999-12-30 2002-07-04 Choi Paula Y. Catechins and green tea extract for the treatment of amyloidosis in alzheimer's disease and other amyloidoses
CA2345767A1 (fr) * 1998-10-16 2000-04-27 Paul Leonce Irma De Nijs Therapie visant a ameliorer la cognition
GB0113663D0 (en) * 2001-06-05 2001-07-25 Novartis Ag Use of organic compounds
TW200501962A (en) * 2003-04-01 2005-01-16 Novartis Ag Use of carbamazepine derivatives for the treatment of agitation in dementia patients

Also Published As

Publication number Publication date
ES2323270T3 (es) 2009-07-10
HRP20050872A2 (en) 2006-12-31
CN1767833A (zh) 2006-05-03
AU2004226805B2 (en) 2008-03-06
DE602004020060D1 (de) 2009-04-30
HK1090543A1 (en) 2006-12-29
RU2005133478A (ru) 2007-06-10
ZA200507439B (en) 2007-06-27
US20090192142A1 (en) 2009-07-30
EP1613328A1 (fr) 2006-01-11
EP1613328B1 (fr) 2009-03-18
IS8096A (is) 2005-10-27
AU2004226805A1 (en) 2004-10-14
EP1613328B8 (fr) 2009-06-10
MXPA05010608A (es) 2005-11-23
NZ542554A (en) 2008-10-31
PT1613328E (pt) 2009-06-15
KR20050121236A (ko) 2005-12-26
ATE425756T1 (de) 2009-04-15
US20070066593A1 (en) 2007-03-22
PL1613328T3 (pl) 2009-08-31
JP2006522050A (ja) 2006-09-28
BRPI0408956A (pt) 2006-04-04
CA2521371A1 (fr) 2004-10-14
TW200501962A (en) 2005-01-16
NO20054994L (no) 2005-10-26
RU2351338C2 (ru) 2009-04-10
WO2004087166A1 (fr) 2004-10-14
TNSN05247A1 (en) 2007-06-11

Similar Documents

Publication Publication Date Title
MA27638A1 (fr) Utilisation de derives de carbamazepine dans le traitement de l&#39;agitation chez des patients atteints de demence
EP1841426A4 (fr) Carbinamines tertiaires incluant des heterocycles substitues, agissant en tant qu&#39;inhibiteurs de la beta-secretase et utilisees dans le traitement de la maladie d&#39;alzheimer
MY138352A (en) Benzothiazole derivatives
NO20050851L (no) Kaspase-inhibitorer og anvendelser derav
TNSN04246A1 (fr) Derives d&#39;heteroarylamides benzocondenses de thienopyridines utiles comme agents therapeutiques, compositions pharmaceutiques les contenant et methodes pour leur utilisation
EP1673078A4 (fr) Inhibiteurs de type benzylether et benzylamino de beta-secretase pour le traitement de la maladie d&#39;alzheimer
PA8583601A1 (es) Derivados de pirrolidona como inhibidores de maob
ATE409176T1 (de) 1-phenylalkancarbonsäurederivate zur behandlung neurodegenerativer erkrankungen
BR0311541A (pt) indol, azaindol e 4-aquenil piperidina amidas heterocìclicas relacionadas
EP1689713A4 (fr) Inhibiteurs de benzylether et benzylamino de beta-secretase pour traiter la maladie d&#39;alzheimer
DE60312736D1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
MY169274A (en) Fused, tricyclic sulfonamide inhibitors of gamma secretase
BR0210392A (pt) Composto, métodos de tratar um paciente que tenha ou de prevenir um paciente de contrair uma doença ou condição e de preparar um composto, e, uso de um composto
MY133512A (en) Non-steroidal il-5 inhibitors, processes and intermediates for their preparation and pharmaceutical compositions comprising said inhibitors
DE602006009556D1 (de) Chinolin-derivate zur behandlung von mglur5-rezeptor-vermittelten erkrankungen
TW200519101A (en) Benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors
EA200601687A1 (ru) Тетрагидроизохинолиновые и тетрагидробензазепиновые производные (варианты), фармацевтическая композиция и фармацевтический набор, лекарственное и эталонное средство для тест-систем на их основе, способ лечения и профилактики заболевания, при котором благоприятна понижающая регуляция или ингибирование экспрессии или функции рецептора igf-1
SE0002729D0 (sv) Novel compound form
ATE519740T1 (de) Tetrahydroindolderivate zur behandlung von alzheimer-krankheit
TW200519102A (en) Hydronopol substituted benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors
TR200103561T2 (tr) Rodanin türevleri ve amiloidlerin önlenmesi ve görüntülenmesinde kullanımları
DE602004008960D1 (de) Verwendung von 1-thiadibenzo e,h azulenen zur herstellung von pharmazeutischen formulierungen für die behandlung und prävention von erkrankungen und störungen des zentralen nervensystems
EA200900313A1 (ru) Производные бензо[1,2,3]тиадиазина
NO20061966L (no) Bicyklo[3.1.1.]heptansubstituerte benzimidazolon- og kinazolinonderivater som agonister for humane ORL1 reseptorer
NO20061813L (no) Benzimidazoion- og kinazolinonderivater som agonister pa humane ORL1 reseptorer